RxDoctor Payments DataLook up a doctor →

Minaxi Patel, MD

Allergy & Immunology · Uniontown, PANPI 1780671859

Payments from drug & device makers

$22,793in general payments, 2019–2025

Across 828 payments — averaging $27.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$5K
  • AstraZeneca$3K
  • Sanofi$2K
  • CSL Behring$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Genentech USA, Inc.$1K
  • plus $7K from 23 others

What the payments were for

  • Food & beverage$22,65099%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,793 in reported general payments places this provider in the 80th percentile of 175 allergy & immunology providers in Pennsylvania.

See all allergy & immunology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$170,987
Medicare patients
126
Services billed
13,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo13$334,071
NucalaMepolizumab18$93,501
CutaquigImmun Glob G(Igg)-Hipp/Maltose15$81,185
HizentraImmun Glob G(Igg)/Pro/Iga 0-5018$80,145
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$61,984
XolairOmalizumab18$45,134
Breo ElliptaFluticasone/Vilanterol16$13,255
Arnuity ElliptaFluticasone Furoate18$7,822
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,234
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$4,650
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$3,377
Tacrolimus11$2,483
Albuterol Sulfate HfaAlbuterol Sulfate79$2,464
Montelukast Sodium226$1,810
Ventolin HfaAlbuterol Sulfate20$1,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro$902$334,07113 claims
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$5,438$182,796134 claims
Octapharma USA, Inc.Cutaquig$35$81,18515 claims
CSL BehringHizentra$2,184$80,14518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 175 allergy & immunology providers in Pennsylvania.

Other allergy & immunology in Uniontown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →